keyword
MENU ▼
Read by QxMD icon Read
search

allogeneic hematopoietic cell transplantation

keyword
https://www.readbyqxmd.com/read/29773600/the-interleukin-3-receptor-cd123-targeted-sl-401-mediates-potent-cytotoxic-activity-against-cd34-cd123-cells-from-acute-myeloid-leukemia-myelodysplastic-syndrome-patients-and-healthy-donors
#1
Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tranh, Xiaokui Mo, Amber Gordon, Donna Bucci, David M Lucas, Alice Mims, Christopher Brooks, Adrienne Dorrance, Alison Walker, William Blum, John C Byrd, Gerard Lozanski, Sumithira Vasu, Natarajan Muthusamy
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least in part due to the failure to eradicate leukemic stem cells or hematopoietic stem cells in myelodysplastic syndrome. CD123, the alpha chain of the interleukin-3 receptor heterodimer, is expressed on the majority of leukemic stem cells and myelodysplastic syndrome hematopoietic stem cells and in 80% of acute myeloid leukemia...
May 17, 2018: Haematologica
https://www.readbyqxmd.com/read/29773298/veno-venous-extracorporeal-membrane-oxygenation-bridged-living-donor-lung-transplantation-for-rapid-progressive-respiratory-failure-with-pleuroparenchymal-fibroelastosis-after-allogeneic-hematopoietic-stem-cell-transplantation
#2
Ayako Shimada, Jiro Terada, Kenji Tsushima, Yoshihisa Tateishi, Ryuzo Abe, Shigeto Oda, Motomu Kobayashi, Masaomi Yamane, Takahiro Oto, Koichiro Tatsumi
Cases of extracorporeal membrane oxygenation (ECMO) bridged lung transplantation (LTx) are rare in Japan because an allocation system to prioritize patients based on urgency remains to be established. For critically ill patients who cannot wait for a brain-dead donor LTx, ECMO bridge to living-donor LTx may be the only practical option. A 21-year-old woman with pleuroparenchymal fibroelastosis after hematopoietic stem cell transplantation was admitted to our hospital with rapidly progressive respiratory failure...
May 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29771974/correction-characteristics-and-risk-of-chronic-graft-versus-host-disease-of-liver-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#3
Chien-Ting Chen, Chun-Yu Liu, Yuan-Bin Yu, Chia-Jen Liu, Liang-Tsai Hsiao, Jyh-Pyng Gau, Tzeon-Jye Chiou, Jing-Hwang Liu, Yao-Chung Liu
[This corrects the article DOI: 10.1371/journal.pone.0185210.].
2018: PloS One
https://www.readbyqxmd.com/read/29770133/peripheral-blood-stem-cell-mobilization-in-healthy-donors-by-granulocyte-colony-stimulating-factor-causes-preferential-mobilization-of-lymphocyte-subsets
#4
Guro Kristin Melve, Elisabeth Ersvaer, Geir Egil Eide, Einar K Kristoffersen, Øystein Bruserud
Background: Allogeneic hematopoietic stem cell transplantation is associated with a high risk of immune-mediated post-transplant complications. Graft depletion of immunocompetent cell subsets is regarded as a possible strategy to reduce this risk without reducing antileukemic immune reactivity. Study design and methods: We investigated the effect of hematopoietic stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) on peripheral blood and stem cell graft levels of various T, B, and NK cell subsets in healthy donors...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29769441/unique-features-and-clinical-importance-of-acute-alloreactive-immune-responses
#5
Charlotte F Inman, Suzy A Eldershaw, Joanne E Croudace, Nathaniel J Davies, Archana Sharma-Oates, Tanuja Rai, Hayden Pearce, Mirjana Sirovica, Y L Tracey Chan, Kriti Verma, Jianmin Zuo, Sandeep Nagra, Francesca Kinsella, Jane Nunnick, Rasoul Amel-Kashipaz, Charles Craddock, Ram Malladi, Paul Moss
Allogeneic stem cell transplantation (allo-SCT) can cure some patients with hematopoietic malignancy, but this relies on the development of a donor T cell alloreactive immune response. T cell activity in the first 2 weeks after allo-SCT is crucial in determining outcome, despite the clinical effects of the early alloreactive immune response often not appearing until later. However, the effect of the allogeneic environment on T cells is difficult to study at this time point due to the effects of profound lymphopenia...
May 17, 2018: JCI Insight
https://www.readbyqxmd.com/read/29769208/infusion-of-alloanergized-donor-lymphocytes-after-cd34-selected-haploidentical-myeloablative-hematopoietic-stem-cell-transplantation
#6
Jeff K Davies, Lisa L Brennan, John Wingard, Christopher R Cogle, Neena Kapoor, Ami J Shah, Bimalangshu R Dey, Thomas R Spitzer, Marcos De Lima, Laurence Jn Cooper, Peter Thall, Richard E Champlin, Lee M Nadler, Eva C Guinan
PURPOSE: Allogeneic haematopoietic stem-cell transplantation (HSCT) is a curative treatment for many haematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) and delayed immune reconstitution. Alloanergization of donor T-cells is a simple approach to rebuild immunity whilst limiting GvHD after haploidentical HSCT but the optimal T-cell dose and impact on immune reconstitution remain unknown.  Experimental Design: We performed a multicentre Phase 1 trial of alloanergized donor lymphocyte infusion (aDLI) after CD34-selected myeloablative haploidentical HSCT...
May 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29766558/a-cure-rate-model-for-q-learning-estimating-an-adaptive-immunosuppressant-treatment-strategy-for-allogeneic-hematopoietic-cell-transplant-patients
#7
Erica E M Moodie, David A Stephens, Shomoita Alam, Mei-Jie Zhang, Brent Logan, Mukta Arora, Stephen Spellman, Elizabeth F Krakow
Cancers treated by transplantation are often curative, but immunosuppressive drugs are required to prevent and (if needed) to treat graft-versus-host disease. Estimation of an optimal adaptive treatment strategy when treatment at either one of two stages of treatment may lead to a cure has not yet been considered. Using a sample of 9563 patients treated for blood and bone cancers by allogeneic hematopoietic cell transplantation drawn from the Center for Blood and Marrow Transplant Research database, we provide a case study of a novel approach to Q-learning for survival data in the presence of a potentially curative treatment, and demonstrate the results differ substantially from an implementation of Q-learning that fails to account for the cure-rate...
May 16, 2018: Biometrical Journal. Biometrische Zeitschrift
https://www.readbyqxmd.com/read/29762865/population-pharmacokinetics-of-vancomycin-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#8
Akira Okada, Misato Kariya, Kei Irie, Yutaka Okada, Nobuhiro Hiramoto, Hisako Hashimoto, Ryosuke Kajioka, Chika Maruyama, Hidefumi Kasai, Mami Hamori, Asako Nishimura, Nobuhito Shibata, Keizo Fukushima, Nobuyuki Sugioka
Vancomycin is a commonly used antimicrobial agent for patients undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Vancomycin has large inter- and intraindividual pharmacokinetic variability, which is mainly described by renal function; various studies have indicated that vancomycin pharmacokinetics are altered in special populations. However, little is known regarding vancomycin pharmacokinetics in patients undergoing allo-HSCT. Therefore, we aimed to develop a population pharmacokinetic (PopPK) model of vancomycin in patients undergoing allo-HSCT for effective and safe antimicrobial therapy and to develop a vancomycin dosing nomogram for a vancomycin optimal-dosing strategy...
May 15, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29761072/sezary-syndrome-manifesting-as-posttransplant-lymphoproliferative-disorder
#9
Thanh-Phuong Afiat, Xiaohui Zhang, Hailing Zhang, Ernesto Ayala, Ling Zhang, Lubomir Sokol
Posttransplant lymphoproliferative disorders (PTLDs) of T-cell orgin are rare biologically heterogeneous diseases of mature lymphoid cells manifesting in immunosuppressed patients. Only a few cases of mycosis fungoides diagnosed post allogeneic hematopoietic cell transplant (alloHSCT) have been described so far. We present a patient with myelodysplastic syndrome (MDS) post matched unrelated donor alloHSCT who was on long-term immunosuppressive therapy due to graft versus host disease. Three years after an alloHSCT, she developed generalized erythroderma and peripheral blood lymphocytosis...
2018: Leukemia Research Reports
https://www.readbyqxmd.com/read/29760731/recovery-of-donor-hematopoiesis-after-graft-failure-and-second-hematopoietic-stem-cell-transplantation-with-intraosseous-administration-of-mesenchymal-stromal-cells
#10
Nataliya Petinati, Nina Drize, Natalia Sats, Natalya Risinskaya, Andrey Sudarikov, Michail Drokov, Daria Dubniak, Alina Kraizman, Maria Nareyko, Natalia Popova, Maya Firsova, Larisa Kuzmina, Elena Parovichnikova, Valeriy Savchenko
Multipotent mesenchymal stromal cells (MSCs) participate in the formation of bone marrow niches for hematopoietic stem cells. Donor MSCs can serve as a source of recovery for niches in patients with graft failure (GF) after allogeneic bone marrow (BM) transplantation. Since only few MSCs reach the BM after intravenous injection, MSCs were implanted into the iliac spine. For 8 patients with GF after allo-BMT, another hematopoietic stem cell transplantation with simultaneous implantation of MSCs from their respective donors into cancellous bone was performed...
2018: Stem Cells International
https://www.readbyqxmd.com/read/29758394/impact-of-thrombotic-microangiopathy-on-renal-outcomes-and-survival-after-hematopoietic-stem-cell-transplantation
#11
Merve Postalcioglu, Haesook T Kim, Faruk Obut, Osman Arif Yilmam, Jiqiao Yang, Benjamin C Byun, Sophie Kupiec-Weglinski, Robert Soiffer, Jerome Ritz, Joseph H Antin, Edwin Alyea, John Koreth, Corey Cutler, Philippe Armand, Julie M Paik, David E Leaf, Vincent T Ho, Reza Abdi
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT). We characterized the incidence, risk factors, and long-term outcomes associated with TA-TMA by performing a comprehensive review of all adult patients (n=1,990) undergoing allogeneic HSCT at the Dana Farber Cancer Institute/Brigham and Women's Hospital between 2005 and 2013. Using the City of Hope criteria, we identified 258 (13%) and 508 (26%) patients with "definite" and "probable" TMA, respectively...
May 11, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29758393/phase-i-trial-of-brentuximab-vedotin-for-steroid-refractory-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation
#12
Zachariah DeFilipp, Shuli Li, Maria E Kempner, Jami Brown, Candice Del Rio, Betsy Valles, Chrisa Hunnewell, Meredith Saylor, Julie Vanderklish, Bimalangshu R Dey, Areej El-Jawahri, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen
We conducted a phase I study of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD). A modified 3+3 study design was used with the primary endpoint to determine the maximum tolerated dose (MTD) of BV in this population. Escalating doses of BV were planned, starting with 0.6 mg/kg q3weeks (dose level 0) and increasing by 0.3 mg/kg per dose level. BV was administered in 21-day cycles for up to 16 cycles of therapy...
May 11, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29754771/epstein-barr-virus-specific-cytokine-induced-killer-cells-for-treatment-of-epstein-barr-virus-related-malignant-lymphoma
#13
Lisa-Marie Pfeffermann, Verena Pfirrmann, Sabine Huenecke, Melanie Bremm, Halvard Bonig, Hans-Michael Kvasnicka, Thomas Klingebiel, Peter Bader, Eva Rettinger
BACKGROUND: Prolonged immunosuppression or delayed T-cell recovery may favor Epstein-Barr virus (EBV) infection or reactivation after allogeneic hematopoietic stem cell transplantation (HSCT), which can lead to post-transplant lymphoproliferative disease (PTLD) and high-grade malignant B-cell lymphoma. Cytokine-induced killer (CIK) cells with dual specific anti-tumor and virus-specific cellular immunity may be applied in this context. METHODS: CIK cells with EBV-specificity were generated from peripheral blood mononuclear cells (PBMCs), expanded in the presence of interferon-γ, anti-CD3, interleukin (IL)-2 and IL-15 and were pulsed twice with EBV consensus peptide pool...
May 10, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29753839/platelet-transfusion-refractoriness-in-single-unit-cord-blood-transplantation-for-adults-risk-factors-and-clinical-outcomes
#14
Susumu Tanoue, Takaaki Konuma, Seiko Kato, Maki Oiwa-Monna, Masamichi Isobe, Koji Jimbo, Satoshi Takahashi, Arinobu Tojo
Platelet transfusion refractoriness (PTR) is frequently observed after allogeneic hematopoietic cell transplantation (HCT). However, the incidence of and risk factors for PTR, and impact of PTR on transplant outcomes after cord blood transplantation (CBT) have not been fully investigated. We retrospectively analyzed 185 adult patients who received single-unit CBT in our institute. The mean 16-hour corrected count increment (CCI) for the 5,840 platelet transfusions was 3.68×109 /l. Among them, 3,196 transfusions (54...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753837/status-of-nk-cell-recovery-in-day-21-bone-marrow-after-allogeneic-hematopoietic-stem-cell-transplantation-predicts-clinical-outcome
#15
Norimichi Hattori, Bungo Saito, Yohei Sasaki, Shotaro Shimada, So Murai, Maasa Abe, Yuta Baba, Megumi Watanuki, Shun Fujiwara, Yukiko Kawaguchi, Nana Arai, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Hiroshi Harada, Tsuyoshi Nakamaki
Rapid immune recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important for clinical outcome prediction. In most studies, immune recovery after allo-HSCT has been monitored via peripheral blood. However, few reports regarding the status of absolute lymphocyte subsets in the bone marrow (BM) microenvironment have been undertaken. Therefore, we evaluated the clinical impact of immune recovery in the early period following allo-HSCT using BM samples. We showed that delayed natural killer (NK) cell recovery was independently associated with a poor prognosis for overall survival (hazard ratio (HR), 3...
May 10, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753698/hematopoietic-stem-cell-transplantation-in-geriatric-patients-in-turkey
#16
REVIEW
Hakan Goker, Engin Kelkitli, Yahya Buyukasik, Haluk Demiroğlu
The incidence of most hematologic malignancies increases with age. Physicians increasingly refer older patients for hematopoietic stem cell transplantation (HSCT) due to more experience and improved supportive care in HSCT. This article discusses the available data regarding the feasibility, tolerability, toxicity, and effectiveness of autologous and allogeneic HSCT in older adults.
April 18, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29753677/multicenter-phase-1-2-application-of-adenovirus-specific-t-cells-in-high-risk-pediatric-patients-after-allogeneic-stem-cell-transplantation
#17
Winnie Ip, Juliana M F Silva, Hubert Gaspar, Arindam Mitra, Shreenal Patel, Kanchan Rao, Robert Chiesa, Persis Amrolia, Kimberly Gilmour, Gul Ahsan, Mary Slatter, Andrew R Gennery, Robert F Wynn, Paul Veys, Waseem Qasim
BACKGROUND: Adenovirus (ADV) reactivation can cause significant morbidity and mortality in children after allogeneic stem cell transplantation. Antiviral drugs can control viremia, but viral clearance requires recovery of cell-mediated immunity. METHOD: This study was an open-label phase 1/2 study to investigate the feasibility of generating donor-derived ADV-specific T cells (Cytovir ADV, Cell Medica) and to assess the safety of pre-emptive administration of ADV-specific T cells in high-risk pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT) to treat adenoviremia...
May 9, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29753163/baseline-renal-function-and-albumin-are-powerful-predictors-for-allogeneic-transplantation-related-mortality
#18
Roni Shouval, Cornelis N de Jong, Joshua Fein, Annoek E C Broers, Ivetta Danylesko, Avichai Shimoni, Marloes R Reurs, Adája E Baars, Niels van der Schaft, Arnon Nagler, Jan J Cornelissen
RATIONALE: Biomarkers measured in blood chemistry before allogeneic hematopoietic stem cell transplantation (HSCT) may reflect patients' physiological status. We hypothesized that selected markers are predictive for non-relapse mortality (NRM) following transplantation and could contribute to risk assessment. PATIENTS AND METHODS: We investigated the value of pre-HSCT albumin, estimated glomerular filtration rate (eGFR) and alkaline phosphatase (AlkP) in predicting NRM...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753160/get-outta-here-addition-of-mobilizing-agents-to-conditioning-regimen-improves-donor-engraftment-after-allogeneic-hematopoietic-stem-cell-transplantation-for-wiskott-aldrich-syndrome
#19
Michael P Rettig
No abstract text is available yet for this article.
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29753159/defining-incidence-and-risk-factors-for-catheter-associated-bloodstream-infections-in-an-outpatient-adult-hematopoietic-cell-transplant-program
#20
Marissa K McDonald, Kathryn A Culos, Katie S Gatwood, Caleb Prow, Heidi Chen, Bipin N Savani, Michael Byrne, Adetola A Kassim, Brian G Engelhardt, Madan Jagasia, Gowri Satyanarayana
BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) patients are at an increased risk of developing central line-associated bloodstream infections (CLABSIs) due to prolonged periods of myelosuppression, immunosuppression, and indwelling catheter days. CLABSIs are among the most serious complications in HCT recipients and can lead to prolonged hospitalizations, intensive care unit (ICU) admissions, lengthy antimicrobial therapies, and increased mortality. There is a lack of data regarding the incidence and risk factors associated with the development of CLABSIs in the HCT population undergoing outpatient transplantation...
May 9, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
120477
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"